GlassScriptPhysician profile
James Steven Robbins
NPI 1720234412
$2,236.55
in general payments reported to CMS, 2019-2025
27 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $194 · 2021: $522 · 2022: $427 · 2023: $229 · 2024: $165 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.68 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $235.11 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $152.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $145.23 | 2019-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.68 | 2019-2020 | |
| Novo Nordisk INC | $130.03 | 2019-2022 | |
| Abbott Laboratories | $91.21 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $84.60 | 2019-2022 | |
| Pfizer INC. | $83.26 | 2019-2025 | |
| Lilly USA, LLC | $82.71 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.87 | 2019-2023 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $71.76 | 2020-2023 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.84 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $30.26 | 2022-2023 | Xarelto |
| Astellas Pharma US INC | $30.05 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $24.45 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.88 | 2021 | |
| Inspire Medical Systems, INC. | $23.19 | 2024 | Inspire |
| Lifescan, INC. | $21.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.45 | 2021 | |
| Quidel Corporation | $16.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.71 | 2021 | |
| Exact Sciences Corporation | $14.46 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $12.89 | 2019 | |
| Smith+Nephew, INC. | $12.68 | 2020 | |
| Amarin Pharma, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.